U.S. markets close in 1 hour 48 minutes
  • S&P 500

    4,131.85
    -31.41 (-0.75%)
     
  • Dow 30

    33,768.98
    -308.65 (-0.91%)
     
  • Nasdaq

    13,771.51
    -143.26 (-1.03%)
     
  • Russell 2000

    2,176.32
    -55.68 (-2.49%)
     
  • Crude Oil

    62.39
    -0.99 (-1.56%)
     
  • Gold

    1,778.40
    +7.80 (+0.44%)
     
  • Silver

    25.86
    +0.02 (+0.09%)
     
  • EUR/USD

    1.2032
    -0.0009 (-0.07%)
     
  • 10-Yr Bond

    1.5620
    -0.0390 (-2.44%)
     
  • GBP/USD

    1.3938
    -0.0046 (-0.33%)
     
  • USD/JPY

    108.1300
    -0.0200 (-0.02%)
     
  • BTC-USD

    55,971.68
    +1,036.38 (+1.89%)
     
  • CMC Crypto 200

    1,275.25
    +40.84 (+3.31%)
     
  • FTSE 100

    6,859.87
    -140.21 (-2.00%)
     
  • Nikkei 225

    29,100.38
    -584.99 (-1.97%)
     

Trade Alert: The Chief Financial Officer Of Syneos Health, Inc. (NASDAQ:SYNH), Jason Meggs, Has Just Spent US$131k Buying Shares

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Potential Syneos Health, Inc. (NASDAQ:SYNH) shareholders may wish to note that the Chief Financial Officer, Jason Meggs, recently bought US$131k worth of stock, paying US$36.74 for each share. That's a very decent purchase to our minds and it grew their holding by a solid 13%.

View our latest analysis for Syneos Health

Syneos Health Insider Transactions Over The Last Year

In fact, the recent purchase by Jason Meggs was the biggest purchase of Syneos Health shares made by an insider individual in the last twelve months, according to our records. So it's clear an insider wanted to buy, at around the current price, which is US$39.46. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. The good news for Syneos Health share holders is that insiders were buying at near the current price.

In the last twelve months Syneos Health insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

NasdaqGS:SYNH Recent Insider Trading, March 25th 2020
NasdaqGS:SYNH Recent Insider Trading, March 25th 2020

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Insider Ownership

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 0.2% of Syneos Health shares, worth about US$8.5m, according to our data. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!

So What Does This Data Suggest About Syneos Health Insiders?

It's certainly positive to see the recent insider purchases. And an analysis of the transactions over the last year also gives us confidence. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Syneos Health insiders are expecting a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Syneos Health. To that end, you should learn about the 3 warning signs we've spotted with Syneos Health (including 1 which is a bit concerning).

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.